Literature DB >> 26865178

Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up.

Masayoshi Okumi1, Kazuya Omoto2, Kohei Unagami3, Hideki Ishida2, Kazunari Tanabe2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26865178     DOI： 10.1007/s11255-016-1234-y

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  5 in total

Review 1.  Atypical hemolytic-uremic syndrome.

Authors:  Marina Noris; Giuseppe Remuzzi
Journal:  N Engl J Med       Date:  2009-10-22       Impact factor: 91.245

Review 2.  Thrombotic microangiopathy after kidney transplantation.

Authors:  Claudio Ponticelli; Giovanni Banfi
Journal:  Transpl Int       Date:  2006-10       Impact factor: 3.782

Review 3.  New insights into postrenal transplant hemolytic uremic syndrome.

Authors:  Julien Zuber; Moglie Le Quintrec; Rebecca Sberro-Soussan; Chantal Loirat; Véronique Frémeaux-Bacchi; Christophe Legendre
Journal:  Nat Rev Nephrol       Date:  2010-11-23       Impact factor: 28.314

4.  Complement mutation-associated de novo thrombotic microangiopathy following kidney transplantation.

Authors:  M Le Quintrec; A Lionet; N Kamar; A Karras; S Barbier; M Buchler; F Fakhouri; F Provost; W H Fridman; E Thervet; C Legendre; J Zuber; V Frémeaux-Bacchi
Journal:  Am J Transplant       Date:  2008-06-28       Impact factor: 8.086

5.  Eculizumab for atypical hemolytic uremic syndrome recurrence in renal transplantation.

Authors:  J Zuber; M Le Quintrec; S Krid; C Bertoye; V Gueutin; A Lahoche; N Heyne; G Ardissino; V Chatelet; L-H Noël; M Hourmant; P Niaudet; V Frémeaux-Bacchi; E Rondeau; C Legendre; C Loirat
Journal:  Am J Transplant       Date:  2012-09-07       Impact factor: 8.086
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.